ArticleOncology letters2018
MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Multi-pathway regulatory role of miR-4693-5p in the modulation of rheumatoid arthritis.Scientific reports · 2025Article
- Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.Cancer biology & therapy · 2023Review
- Generation of TRIM28 Knockout K562 Cells by CRISPR/Cas9 Genome Editing and Characterization of TRIM28-Regulated Gene Expression in Cell Proliferation and Hemoglobin Beta Subunits.International journal of molecular sciences · 2022Article
- miR-874: An Important Regulator in Human Diseases.Frontiers in cell and developmental biology · 2022Review
- MiR-874 Inhibits Cell Proliferation, Migration, and Invasion of Glioma Cells and Correlates with Prognosis of Glioma Patients.Neuromolecular medicine · 2021Article
- CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents.Frontiers in oncology · 2021Review
- Advances in the role of miRNAs in the occurrence and development of osteosarcoma.Open medicine (Warsaw, Poland) · 2020Article
- Circ_0005576 Promotes Malignant Progression Through miR-874/CDK8 Axis in Colorectal Cancer.OncoTargets and therapy · 2020Article
- miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16.International journal of oncology · 2019Article
- Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) perform important roles in the development and progression of human malignancy. miR-874, as a tumor suppressor, is decreased in malignant tumors, including osteosarcoma. However, the potential mechanism of miR-874 in osteosarcoma remains largely unknown. In the present study, a dual-luciferase reporter system supported cyclin-dependent kinase 9 (CDK9) as a direct target gene of miR-874. miR-874 mimics evidently repressed CDK9 expression in osteosarcoma. Furthermore, osteosarcoma tissues and cell lines exhibited increased expression of CDK9, and CDK9 expression levels were inversely correlated (R=-0.725) with that of miR-874 in osteosarcoma tissues. Finally, CDK9 overexpression reversed the potential effect of miR-874 on the proliferation and invasion of osteosarcoma cells. Overall, the results revealed that miR-874, as a tumor suppressor, is involved in osteosarcoma progression and metastasis by targeting CDK9, indicating that the miR-874/CDK9 pathway may serve as a potential therapeutic target for the treatment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.